All GLG News Analyses Filed Under: Cardiology

Regadenoson is similar to the drug it's set to replace, adenosine, in terms of its ability to increase coronary flow and detect coronary artery disease. However, it's easier to use (it's given as a bolus as opposed to an infusion over 3-5 minutes) and seems to have less side effects. It also has a longer...

This study should make practictioners more aware of potential side effects of the therapy for HIV. It is now a "chronic" disease and needs to be thought of in that way. Fortunately we have other drugs to use, but need to be on the lookout for long term side effects with them as well. What this teaches...

Pfizer announced today that Lipitor® (atorvastatin calcium) 80 mg showed unexpectedly potent reduction in myocardial ischemiaLipitor significantly reduced the average number of ischemic events by nearly 70 percent and total duration of events by more than 60 percent from baseline to week 18 of...

Treating non LDL cholesterol is becoming more important. The more drugs we have the better. At some point we will be able to see which is better.

Vytorin was/is good to lower LDL. We need meds to lower non LDL and raise HDL.  This med if it truly has fewer side effects may accomplish this.

Lipitor is the only statin tested to reduce ischemic stroke. The new study also proved its role in reduce angina and MI

 A bottle of 30 Generic Zyrtec can be purchased for $15.  No one is going to get Xyzal that inexpensively. There are no head to head studies showing Xyzal to be better than Zyrtec.  Even though Xyzal claims a 6% sedation rate compared to Zyrtec's 14% rate, it's not apples to apples. ...

The potential side effect of liver damage of the new cholesterol agent from Merck will definitely slow or even halt the FDA approval of the medication.

There is no question that prasugel is a good drug. Side effects are an issue. If approved, its use needs to be somewhat restricted.

The decision by Takeda to halt development of TAK-475, is not surprising considering the problems faced now by companies trying to get regulatory approval for new lipid-lowering drugs. TAK-475 was not more potent, but was thought to have a better safety profile than statins. However, because the safety...